Drug intelligence / Profile preview

TheraFill

Development stage: Unknown
Lead developer: Sewon Cellontech
Modality: Recombinant Proteins and Enzymes
Administration: Intradermal

Overview

TheraFill is a sterile, injectable dermal filler composed of highly purified porcine-derived atelocollagen. It is indicated for the correction of facial wrinkles and folds, such as nasolabial folds, through soft-tissue augmentation. The product is manufactured by removing the immunogenic telopeptides from porcine collagen, resulting in atelocollagen that is highly biocompatible and similar in structure to human dermal collagen. Unlike bovine-derived fillers, TheraFill does not carry the risk of bovine spongiform encephalopathy (BSE) and typically does not require pre-injection skin testing. It acts as a scaffold that supports cellular influx and tissue reconstruction at the injection site.

Brand names: TheraFill
Other names: porcine atelocollagenporcine collagen filleratelocollagen

Beyond the preview

Go deeper on TheraFill.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TheraFill.

Explore the full profile